Fig. 7
ALK inhibition reduces proliferation of CRC patient-derived organoids in vitro and slows tumour growth in a CMS1 xenograft model. A Organoids’ proliferation assessment performed with AlamarBlue after 8/14 days of CZB treatment. Organoids were seeded in 2% BME and CZB treatment was added the following day at the indicated concentrations. Statistics were calculated by one-way ANOVA test. B SW48 cells (1 × 106 per animal) were subcutaneously implanted in Nude Foxn1nu mice. Tumor bearing mice were treated with either vehicle control or crizotinib (50 mg/kg/day), by oral gavage. Mice were euthanized when tumor size reached 1.500 mm3. Data are means ± SEM from each group (n = 7 per treatment group). C Survival assessment of Nude Foxn1nu mice from experiment in C. Animal survival percentage is increased in CZB-treated group compared to the control. D Heatmap showing ALK mRNA expression measured with qPCR in tumors collected at the endpoint from experiment in C. E Histological evaluation of SW48 xenograft tumors extracted from mice by means of ALK abundance (scale bar: 50 μm) and H&E (scale bar: 400 μm)